BMS has announced they have filed a new drug application with the FDA and EMA for Deucravacitinib, a TYK2 inhibitor, to treat adults with moderate to severe plaque psoriasis. (w/ a PDUFA goal date of 9/10/2022) https://t.co/w5YmRYdXm4